Iterum Therapeutics (NASDAQ:ITRM) announced its quarterly earnings results on Thursday. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.38) by ($0.22), Fidelity Earnings reports.
Shares of ITRM opened at $0.52 on Friday. The stock has a 50-day moving average of $0.73 and a two-hundred day moving average of $1.36. Iterum Therapeutics has a one year low of $0.45 and a one year high of $7.19. The stock has a market cap of $11.04 million, a P/E ratio of -0.09 and a beta of 0.90.
ITRM has been the subject of a number of recent analyst reports. Royal Bank of Canada reissued a “hold” rating and issued a $2.00 price objective on shares of Iterum Therapeutics in a research report on Monday, August 10th. Zacks Investment Research cut Iterum Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 5th. Finally, SVB Leerink raised their price objective on Iterum Therapeutics from $1.00 to $1.50 and gave the stock a “market perform” rating in a research report on Thursday, October 1st. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company. Iterum Therapeutics currently has an average rating of “Hold” and an average target price of $4.70.
Iterum Therapeutics Company Profile
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a novel penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
See Also: Momentum Indicators
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.